Zelluna Immunotherapy AS is a privately owned biopharmaceutical company at the forefront of developing TCR based immunotherapies. With a focus on eliminating solid cancers, Zelluna Immunotherapy pioneers the development of off the shelf T cell receptor (TCR) guided natural killer (NK) cell therapies. Their goal is to unleash the most powerful elements of the immune system in order to treat cancer patients effectively.

Supported by an experienced team of biotech entrepreneurs and an international board, Zelluna combines the broad target range of TCRs with the high potency and allogeneic nature of NK cells. This innovative approach allows them to generate transformative cell therapy products that can be readily supplied to patients with solid tumors and high unmet medical needs. Zelluna Immunotherapy prides itself on fostering an amazing culture and working environment while pushing the boundaries of scientific innovation.

They are committed to excellence in drug development and are actively looking to collaborate and expand their pipeline. For career opportunities or inquiries, please reach out to the provided contact information. Join Zelluna in their pioneering mission to move cancer treatment in the right direction